Gene therapy (in longevity context)

Gene therapy delivers genetic material to add, silence, or edit genes — typically via AAV vectors for stable transgene expression and lipid nanoparticles for transient nucleic-acid delivery (e.g., mRNA, gene-editing components). Longevity targets include telomerase (TERT), follistatin, Klotho, and partial reprogramming via OSK (Oct4, Sox2, Klf4 — three Yamanaka factors, omitting c-Myc to reduce oncogenicity). Rodent data are strong for some constructs, but human applications remain pre-clinical or run as small offshore or patient-paid programs outside FDA-regulated frameworks (BioViva, Libella). Risks include immunogenicity, oncogenicity, and off-target editing; no anti-aging gene therapy is approved.